{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:52:30Z","timestamp":1778629950117,"version":"3.51.4"},"reference-count":96,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1212\/con.0000000000000541","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T17:05:38Z","timestamp":1512493538000},"page":"1680-1708","source":"Crossref","is-referenced-by-count":12,"title":["Common Histologically Benign Tumors of the Brain"],"prefix":"10.1212","volume":"23","author":[{"suffix":"III","given":"Roy E.","family":"Strowd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009\u20132013","volume":"18","author":"Ostrom QT","year":"2016","unstructured":"Ostrom QT Gittleman H Xu J. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009\u20132013. Neuro Oncol 2016;18:v1\u2013v75. doi:10.1093\/neuonc\/now207.","journal-title":"Neuro Oncol"},{"issue":"5","key":"e_1_3_1_3_2","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nos218","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005\u20132009","volume":"14","author":"Dolecek TA","year":"2012","unstructured":"Dolecek TA Propp JM Stroup NE Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005\u20132009. Neuro Oncol 2012;14(suppl 5):v1\u2013v49. doi:10.1093\/neuonc\/nos218.","journal-title":"Neuro Oncol"},{"issue":"6","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis DN","year":"2016","unstructured":"Louis DN Perry A Reifenberger G. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131(6):803\u2013820. doi:10.1007\/s00401\u2013016\u20131545\u20131.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis DN","year":"2007","unstructured":"Louis DN Ohgaki H Wiestler OD. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97\u2013109. doi:10.1007\/s00401\u2013007\u20130243\u20134.","journal-title":"Acta Neuropathol"},{"key":"e_1_3_1_6_2","volume-title":"WHO classification of tumours of the central nervous system","author":"International Agency for Research on Cancer","year":"2016","unstructured":"International Agency for Research on Cancer; Louis DN Ohgaki H Wiestler OD Cavenee WK, editors. WHO classification of tumours of the central nervous system. 4th ed. Lyon, France: World Health Organization, 2016.","edition":"4"},{"issue":"4","key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012","volume":"17","author":"Ostrom QT","year":"2015","unstructured":"Ostrom QT Gittleman H Fulop J. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol 2015;17(suppl 4):iv1\u2013iv62. doi:10.1093\/neuonc\/nov189.","journal-title":"Neuro Oncol"},{"issue":"1","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3171\/2016.1.JNS151842","article-title":"Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization grade I meningioma","volume":"126","author":"Nanda A","year":"2017","unstructured":"Nanda A Bir SC Maiti TK. Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization grade I meningioma. J Neurosurg 2017;126(1):201\u2013211. doi:10.3171\/2016.1.JNS151842.","journal-title":"J Neurosurg"},{"issue":"14","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/cncr.29379","article-title":"Epidemiology of meningiomas post-Public Law 107\u2013206: the Benign Brain Tumor Cancer Registries Amendment Act","volume":"121","author":"Dolecek TA","year":"2015","unstructured":"Dolecek TA Dressler EV Thakkar JP. Epidemiology of meningiomas post-Public Law 107\u2013206: the Benign Brain Tumor Cancer Registries Amendment Act. Cancer 2015;121(14):2400\u20132410. doi:10.1002\/cncr.29379.","journal-title":"Cancer"},{"issue":"1","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0404.1970.tb05608.x","article-title":"Intracranial meningioma\u2014a population study of ten years","volume":"46","author":"Rausing A","year":"1970","unstructured":"Rausing A Ybo W Stenflo J. Intracranial meningioma\u2014a population study of ten years. Acta Neurol Scand 1970;46(1):102\u2013110. doi:10.1111\/j.1600\u20130404.1970.tb05608.x.","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"e_1_3_1_11_2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/cncr.20088","article-title":"Frequency and risk factors for meningioma in clinically healthy 75-year-old patients: results of the transdanube ageing study (VITA)","volume":"100","author":"Krampla W","year":"2004","unstructured":"Krampla W Newrkla S Pfisterer W. Frequency and risk factors for meningioma in clinically healthy 75-year-old patients: results of the transdanube ageing study (VITA). Cancer 2004;100(6):1208\u20131212. doi:10.1002\/cncr.20088.","journal-title":"Cancer"},{"issue":"1","key":"e_1_3_1_12_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-006-9146-9","article-title":"Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression","volume":"80","author":"Korhonen K","year":"2006","unstructured":"Korhonen K Salminen T Raitanen J. Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol 2006;80(1):1\u20137. doi:10.1007\/s11060\u2013006\u20139146\u20139.","journal-title":"J Neurooncol"},{"issue":"11","key":"e_1_3_1_13_2","doi-asserted-by":"crossref","first-page":"11579","DOI":"10.1007\/s13277-014-2448-1","article-title":"Reproductive factors in relation to risk of brain tumors in women: an updated meta-analysis of 27 independent studies","volume":"35","author":"Zong H","year":"2014","unstructured":"Zong H Xu H Geng Z. Reproductive factors in relation to risk of brain tumors in women: an updated meta-analysis of 27 independent studies. Tumour Biol 2014;35(11):11579\u201311586. doi:10.1007\/s13277\u2013014\u20132448\u20131.","journal-title":"Tumour Biol"},{"issue":"2","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11060-014-1427-0","article-title":"Reproductive factors and risk of primary brain tumors in women","volume":"118","author":"Anic GM","year":"2014","unstructured":"Anic GM Madden MH Nabors LB. Reproductive factors and risk of primary brain tumors in women. J Neurooncol 2014;118(2):297\u2013304. doi:10.1007\/s11060\u2013014\u20131427\u20130.","journal-title":"J Neurooncol"},{"issue":"3","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3171\/2012.9.JNS12811","article-title":"Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females","volume":"118","author":"Claus EB","year":"2013","unstructured":"Claus EB Calvocoressi L Bondy ML. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg 2013;118(3):649\u2013656. doi:10.3171\/2012.9.JNS12811.","journal-title":"J Neurosurg"},{"issue":"2","key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.canep.2011.08.003","article-title":"Hormonal therapies and meningioma: is there a link?","volume":"36","author":"Cea-Soriano L","year":"2012","unstructured":"Cea-Soriano L Blenk T Wallander MA Rodr\u00edguez LA. Hormonal therapies and meningioma: is there a link? Cancer Epidemiol 2012;36(2):198\u2013205. doi:10.1016\/j.canep.2011.08.003.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"e_1_3_1_17_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijgo.2008.11.037","article-title":"Obstetric outcomes of women with intracranial neoplasms","volume":"105","author":"Johnson N","year":"2009","unstructured":"Johnson N Sermer M Lausman A Maxwell C. Obstetric outcomes of women with intracranial neoplasms. Int J Gynaecol Obstet 2009;105(1):56\u201359. doi:10.1016\/j.ijgo.2008.11.037.","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"e_1_3_1_18_2","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3171\/jns.1991.75.4.0564","article-title":"Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature","volume":"75","author":"Harrison MJ","year":"1991","unstructured":"Harrison MJ Wolfe DE Lau TS. Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature. J Neurosurg 1991;75(4):564\u2013574.","journal-title":"J Neurosurg"},{"issue":"5","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.3171\/FOC\/2008\/24\/5\/E7","article-title":"Radiation-induced meningioma","volume":"24","author":"Umansky F","year":"2008","unstructured":"Umansky F Shoshan Y Rosenthal G. Radiation-induced meningioma. Neurosurg Focus 2008;24(5):E7. doi:10.3171\/FOC\/2008\/24\/5\/E7.","journal-title":"Neurosurg Focus"},{"issue":"5","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/02688699550040918","article-title":"Intracranial meningiomas following irradiation\u2014a growing problem?","volume":"9","author":"Musa BS","year":"1995","unstructured":"Musa BS Pople IK Cummins BH. Intracranial meningiomas following irradiation\u2014a growing problem? Br J Neurosurg 1995;9(5):629\u2013637. doi:10.1080\/02688699550040918.","journal-title":"Br J Neurosurg"},{"key":"e_1_3_1_21_2","unstructured":"Louis DN Ohgaki H Wiestler OD Cavenee WK editors. WHO classification of tumours of the central nervous system. 4th ed. Geneva Switzerland: World Health Organization 2017."},{"issue":"10","key":"e_1_3_1_22_2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/jmedgenet-2015-103290","article-title":"Clinical and molecular predictors of mortality in neurofibromatosis 2: A UK national analysis of 1192 patients","volume":"52","author":"Hexter A","year":"2015","unstructured":"Hexter A Jones A Joe H. Clinical and molecular predictors of mortality in neurofibromatosis 2: A UK national analysis of 1192 patients. J Med Genet 2015;52(10):699\u2013705. doi:10.1136\/jmedgenet-2015\u2013103290.","journal-title":"J Med Genet"},{"issue":"8","key":"e_1_3_1_23_2","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/neuonc\/nos129","article-title":"Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features","volume":"14","author":"Goutagny S","year":"2012","unstructured":"Goutagny S Bah AB Henin D. Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol 2012;14(8):1090\u20131096. doi:10.1093\/neuonc\/nos129.","journal-title":"Neuro Oncol"},{"issue":"6","key":"e_1_3_1_24_2","first-page":"1022","article-title":"Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas","volume":"54","author":"Lekanne Deprez RH","year":"1994","unstructured":"Lekanne Deprez RH Bianchi AB Groen NA. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet 1994;54(6):1022\u20131029.","journal-title":"Am J Hum Genet"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1471-2164-8-16","article-title":"Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus","volume":"8","author":"Hansson CM","year":"2007","unstructured":"Hansson CM Buckley PG Grigelioniene G. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genomics 2007;8:16. doi:10.1186\/1471\u20132164\u20138\u201316.","journal-title":"BMC Genomics"},{"issue":"3","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.909","article-title":"NF2 status of meningiomas is associated with tumour localization and histology","volume":"194","author":"Kros J","year":"2001","unstructured":"Kros J de Greve K van Tilborg A. NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 2001;194(3):367\u2013372. doi:10.1002\/path.909.","journal-title":"J Pathol"},{"issue":"2","key":"e_1_3_1_27_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10048-012-0319-8","article-title":"Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis","volume":"13","author":"Smith MJ","year":"2012","unstructured":"Smith MJ Wallace AJ Bowers NL. Frequency of SMARCB1 mutations in familial and sporadic schwannomatosis. Neurogenetics 2012;13(2):141\u2013145. doi:10.1007\/s10048\u2013012\u20130319\u20138.","journal-title":"Neurogenetics"},{"issue":"9","key":"e_1_3_1_28_2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00701-015-2495-4","article-title":"Intracranial meningiomas and seizures: a review of the literature","volume":"157","author":"Xue H","year":"2015","unstructured":"Xue H Sveinsson O Tomson T Mathiesen T. Intracranial meningiomas and seizures: a review of the literature. Acta Neurochir (Wien) 2015;157(9):1541\u20131548. doi:10.1007\/s00701\u2013015\u20132495\u20134.","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"e_1_3_1_29_2","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.3171\/foc.1997.2.4.5","article-title":"Prognostic variables in surgery for skull base meningiomas","volume":"2","author":"Lefkowitz MA","year":"1997","unstructured":"Lefkowitz MA Hinton DR Weiss MH. Prognostic variables in surgery for skull base meningiomas. Neurosurg Focus 1997;2(4):e2. doi:10.3171\/foc.1997.2.4.5.","journal-title":"Neurosurg Focus"},{"issue":"3","key":"e_1_3_1_30_2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-010-0386-3","article-title":"Epidemiology and etiology of meningioma","volume":"99","author":"Wiemels J","year":"2010","unstructured":"Wiemels J Wrensch M Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010;99(3):307\u2013314. doi:10.1007\/s11060\u2013010\u20130386\u20133.","journal-title":"J Neurooncol"},{"issue":"6","key":"e_1_3_1_31_2","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/neuonc\/nov285","article-title":"Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade","volume":"18","author":"Hwang WL","year":"2016","unstructured":"Hwang WL Marciscano AE Niemierko A. Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade. Neuro Oncol 2016;18(6):863\u2013872. doi:10.1093\/neuonc\/nov285.","journal-title":"Neuro Oncol"},{"issue":"1","key":"e_1_3_1_32_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3171\/2012.3.JNS111945","article-title":"Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO grade I meningiomas","volume":"117","author":"Oya S","year":"2012","unstructured":"Oya S Kawai K Nakatomi H Saito N. Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO grade I meningiomas. J Neurosurg 2012;117(1):121\u2013128. doi:10.3171\/2012.3.JNS111945.","journal-title":"J Neurosurg"},{"key":"e_1_3_1_33_2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines. Central nervous system cancers. nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf. Accessed October 10 2017."},{"issue":"11","key":"e_1_3_1_34_2","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jocn.2015.03.054","article-title":"Atypical and malignant meningiomas: considerations for treatment and efficacy of radiotherapy","volume":"22","author":"Cain SA","year":"2015","unstructured":"Cain SA Smoll NR Van Heerden J. Atypical and malignant meningiomas: considerations for treatment and efficacy of radiotherapy. J Clin Neurosci 2015;22(11):1742\u20131748. doi:10.1016\/j.jocn.2015.03.054.","journal-title":"J Clin Neurosci"},{"issue":"5","key":"e_1_3_1_35_2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley JO","year":"2016","unstructured":"Blakeley JO Plotkin SR. Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol 2016;18(5):624\u2013638. doi:10.1093\/neuonc\/nov200.","journal-title":"Neuro Oncol"},{"key":"e_1_3_1_36_2","first-page":"1","article-title":"Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review","author":"Graillon T","year":"2016","unstructured":"Graillon T Romano D Defilles C. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. J Neurosurg 2016:1\u201310. doi:10.3171\/2016.8.JNS16995.","journal-title":"J Neurosurg"},{"issue":"1","key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley TJ","year":"2015","unstructured":"Kaley TJ Wen P Schiff D. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol 2015;17(1):116\u2013121. doi:10.1093\/neuonc\/nou148.","journal-title":"Neuro Oncol"},{"key":"e_1_3_1_38_2","unstructured":"Clinicaltrials.gov website. Vismodegib and FAK inhibitor GSK2256098 in treating patients with progressive meningiomas (NCT02523014). clinicaltrials.gov\/ct2\/show\/NCT02523014. Updated August 15 2017. Accessed October 10 2017."},{"key":"e_1_3_1_39_2","unstructured":"Clinicaltrials.gov website. AZD2014 in NF2 patients with progressive or symptomatic meningiomas (NCT02831257). clinicaltrials.gov\/ct2\/show\/NCT02831257. Updated March 27 2017. Accessed October 10 2017."},{"key":"e_1_3_1_40_2","unstructured":"Clinicaltrials.gov website. A study of nivolumab in adult participants with recurrent high-grade meningioma (NCT02648997). clinicaltrials.gov\/ct2\/show\/NCT02648997. Updated April 20 2017. Accessed October 10 2017."},{"key":"e_1_3_1_41_2","unstructured":"Clinicaltrials.gov website. A trial of pembrolizumab for refractory atypical and anaplastic meningioma (NCT03016091). clinicaltrials.gov\/ct2\/show\/NCT03016091. Updated April 27 2017. Accessed October 10 2017."},{"issue":"2","key":"e_1_3_1_42_2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/archotol.130.2.216","article-title":"What is the real incidence of vestibular schwannoma?","volume":"130","author":"Tos M","year":"2004","unstructured":"Tos M Stangerup SE Cay\u00e9-Thomasen P. What is the real incidence of vestibular schwannoma? Arch Otolaryngol Head Neck Surg 2004;130(2):216\u2013220. doi:10.1001\/archotol.130.2.216.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"2","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archotol.1975.00780310013004","article-title":"Occult schwannomas of the vestibular nerve","volume":"101","author":"Stewart TJ","year":"1975","unstructured":"Stewart TJ Liland J Schuknecht HF. Occult schwannomas of the vestibular nerve. Arch Otolaryngol 1975;101(2):91\u201395. doi:10.1001\/archotol.1975.00780310013004.","journal-title":"Arch Otolaryngol"},{"issue":"2","key":"e_1_3_1_44_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s11060-015-1827-9","article-title":"Incidence of vestibular schwannomas in the United States","volume":"124","author":"Kshettry VR","year":"2015","unstructured":"Kshettry VR Hsieh JK Ostrom QT. Incidence of vestibular schwannomas in the United States. J Neurooncol 2015;124(2):223\u2013228. doi:10.1007\/s11060\u2013015\u20131827\u20139.","journal-title":"J Neurooncol"},{"issue":"3","key":"e_1_3_1_45_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archotol.131.3.241","article-title":"The prevalence of \u201cincidental\u201d acoustic neuroma","volume":"131","author":"Lin D","year":"2005","unstructured":"Lin D Hegarty JL Fischbein NJ Jackler RK. The prevalence of \u201cincidental\u201d acoustic neuroma. Arch Otolaryngol Head Neck Surg 2005;131(3):241\u2013244. doi:10.1001\/archotol.131.3.241.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"e_1_3_1_46_2","first-page":"605","article-title":"Transtemporal bone microsurgical removal of acoustic neuromas. The pathology of acoustic neuromas","volume":"80","author":"Dykstra PC","year":"1964","unstructured":"Dykstra PC. Transtemporal bone microsurgical removal of acoustic neuromas. The pathology of acoustic neuromas. Arch Otolaryngol 1964;80:605\u2013616.","journal-title":"Arch Otolaryngol"},{"issue":"1","key":"e_1_3_1_47_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1227\/NEU.0000000000001414","article-title":"Ten-year follow-up on tumor growth and hearing in patients observed with an intracanalicular vestibular schwannoma","volume":"80","author":"Kirchmann M","year":"2017","unstructured":"Kirchmann M Karnov K Hansen S. Ten-year follow-up on tumor growth and hearing in patients observed with an intracanalicular vestibular schwannoma. Neurosurgery 2017;80(1):49\u201356. doi:10.1227\/NEU.0000000000001414.","journal-title":"Neurosurgery"},{"issue":"12","key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1002\/1097-0142(19830615)51:12<2159::AID-CNCR2820511202>3.0.CO;2-L","article-title":"Neurilemomas and salivary gland tumors of the head and neck following childhood irradiation","volume":"51","author":"Shore-Freedman E","year":"1983","unstructured":"Shore-Freedman E Abrahams C Recant W Schneider AB. Neurilemomas and salivary gland tumors of the head and neck following childhood irradiation. Cancer 1983;51(12):2159\u20132163. doi:10.1002\/1097\u20130142(19830615)51:12<2159::AID-CNCR2820511202>3.0.CO;2-L.","journal-title":"Cancer"},{"issue":"1","key":"e_1_3_1_49_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/aje\/kwu081","article-title":"Loud noise exposure and acoustic neuroma","volume":"180","author":"Fisher JL","year":"2014","unstructured":"Fisher JL Pettersson D Palmisano S. Loud noise exposure and acoustic neuroma. Am J Epidemiol 2014;180(1):58\u201367. doi:10.1093\/aje\/kwu081.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"e_1_3_1_50_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/jes.2014.76","article-title":"Validation of self-reported start year of mobile phone use in a Swedish case-control study on radiofrequency fields and acoustic neuroma risk","volume":"25","author":"Pettersson D","year":"2015","unstructured":"Pettersson D Bottai M Mathiesen T. Validation of self-reported start year of mobile phone use in a Swedish case-control study on radiofrequency fields and acoustic neuroma risk. J Expo Sci Environ Epidemiol 2015;25(1):72\u201379. doi:10.1038\/jes.2014.76.","journal-title":"J Expo Sci Environ Epidemiol"},{"issue":"2","key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/EDE.0000000000000058","article-title":"Long-term mobile phone use and acoustic neuroma risk","volume":"25","author":"Pettersson D","year":"2014","unstructured":"Pettersson D Mathiesen T Prochazka M. Long-term mobile phone use and acoustic neuroma risk. Epidemiology 2014;25(2):233\u2013241. doi:10.1097\/EDE.0000000000000058.","journal-title":"Epidemiology"},{"issue":"1","key":"e_1_3_1_52_2","first-page":"1","article-title":"Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation","volume":"40","author":"Matthies C","year":"1997","unstructured":"Matthies C Samii M. Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation. Neurosurgery 1997;40(1):1\u20139; discussion 9\u201310. doi:10.1097\/00006123\u2013199701000\u201300001.","journal-title":"Neurosurgery"},{"issue":"3","key":"e_1_3_1_53_2","first-page":"469","article-title":"Management of vestibular schwannomas (acoustic neuromas): Radiological features in 202 cases\u2013their value for diagnosis and their predictive importance","volume":"40","author":"Matthies C","year":"1997","unstructured":"Matthies C Samii M Krebs S. Management of vestibular schwannomas (acoustic neuromas): Radiological features in 202 cases\u2013their value for diagnosis and their predictive importance. Neurosurgery 1997;40(3):469\u2013482.","journal-title":"Neurosurgery"},{"issue":"5","key":"e_1_3_1_54_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/02688699844619","article-title":"Regrowth of the residual tumour after acoustic neurinoma surgery","volume":"12","author":"Ohta S","year":"1998","unstructured":"Ohta S Yokoyama T Nishizawa S Uemura K. Regrowth of the residual tumour after acoustic neurinoma surgery. Br J Neurosurg 1998;12(5):419\u2013422.","journal-title":"Br J Neurosurg"},{"issue":"8","key":"e_1_3_1_55_2","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/00005537-200308000-00013","article-title":"Surgical excision of acoustic neuroma: Patient outcome and provider caseload","volume":"113","author":"Barker FG","year":"2003","unstructured":"Barker FG2nd Carter BS Ojemann RG. Surgical excision of acoustic neuroma: Patient outcome and provider caseload. Laryngoscope 2003;113(8):1332\u20131343.","journal-title":"Laryngoscope"},{"issue":"1","key":"e_1_3_1_56_2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00006123-199707000-00012","article-title":"Acoustic neuromas: results of current surgical management","volume":"41","author":"Gormley WB","year":"1997","unstructured":"Gormley WB Sekhar LN Wright DC. Acoustic neuromas: results of current surgical management. Neurosurgery 1997;41(1):50\u201358; discussion 58\u201360. doi:10.1097\/00006123\u2013199707000\u201300012.","journal-title":"Neurosurgery"},{"issue":"1","key":"e_1_3_1_57_2","first-page":"11","article-title":"Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them","volume":"40","author":"Samii M","year":"1997","unstructured":"Samii M Matthies C. Management of 1000 vestibular schwannomas (acoustic neuromas): surgical management and results with an emphasis on complications and how to avoid them. Neurosurgery 1997;40(1):11\u201321; discussion 21\u201323. doi:10.1097\/00006123\u2013199701000\u201300002.","journal-title":"Neurosurgery"},{"issue":"7","key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1468-2982.2008.01790.x","article-title":"Headache syndromes after acoustic neuroma surgery and their implications for quality of life","volume":"29","author":"Schankin CJ","year":"2009","unstructured":"Schankin CJ Gall C Straube A. Headache syndromes after acoustic neuroma surgery and their implications for quality of life. Cephalalgia 2009;29(7):760\u2013771. doi:10.1111\/j.1468\u20132982.2008.01790.x.","journal-title":"Cephalalgia"},{"issue":"20","key":"e_1_3_1_59_2","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJM199811123392003","article-title":"Long-term outcomes after radiosurgery for acoustic neuromas","volume":"339","author":"Kondziolka D","year":"1998","unstructured":"Kondziolka D Lunsford LD McLaughlin MR Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med 1998;339(20):1426\u20131433. doi:10.1056\/NEJM199811123392003.","journal-title":"N Engl J Med"},{"issue":"8","key":"e_1_3_1_60_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jmedgenet-2015-103050","article-title":"Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis type 2","volume":"52","author":"Stivaros SM","year":"2015","unstructured":"Stivaros SM Stemmer-Rachamimov AO Alston R. Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis type 2. J Med Genet 2015;52(8):557\u2013562. doi:10.1136\/jmedgenet-2015\u2013103050.","journal-title":"J Med Genet"},{"issue":"4","key":"e_1_3_1_61_2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/neuonc\/nou317","article-title":"Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas","volume":"17","author":"Dewan R","year":"2015","unstructured":"Dewan R Pemov A Kim HJ. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro Oncol 2015;17(4):566\u2013573. doi:10.1093\/neuonc\/nou317.","journal-title":"Neuro Oncol"},{"key":"e_1_3_1_62_2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3171\/2014.8.GKS141503","article-title":"Long-term follow-up studies of gamma knife surgery for patients with neurofibromatosis type 2","volume":"121","author":"Sun S","year":"2014","unstructured":"Sun S Liu A. Long-term follow-up studies of gamma knife surgery for patients with neurofibromatosis type 2. J Neurosurg 2014;121(suppl):143\u2013149. doi:10.3171\/2014.8.GKS141503.","journal-title":"J Neurosurg"},{"issue":"4","key":"e_1_3_1_63_2","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1054\/bjoc.1999.1030","article-title":"Neurofibromatosis 2, radiosurgery and malignant nervous system tumours","volume":"82","author":"Baser ME","year":"2000","unstructured":"Baser ME Evans DG Jackler RK. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 2000;82(4):998. doi:10.1054\/bjoc.1999.1030.","journal-title":"Br J Cancer"},{"issue":"14","key":"e_1_3_1_64_2","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","article-title":"Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas","volume":"34","author":"Blakeley JO","year":"2016","unstructured":"Blakeley JO Ye X Duda DG. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J Clin Oncol 2016;34(14):1669\u20131675. doi:10.1200\/JCO.2015.64.3817.","journal-title":"J Clin Oncol"},{"issue":"4","key":"e_1_3_1_65_2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin SR","year":"2009","unstructured":"Plotkin SR Stemmer-Rachamimov AO Barker FG2nd. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009;361(4):358\u2013367. doi:10.1056\/NEJMoa0902579.","journal-title":"N Engl J Med"},{"issue":"6","key":"e_1_3_1_66_2","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00280-014-2456-2","article-title":"Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients","volume":"73","author":"Slusarz KM","year":"2014","unstructured":"Slusarz KM Merker VL Muzikansky A. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 2014;73(6):1197\u20131204. doi:10.1007\/s00280\u2013014\u20132456\u20132.","journal-title":"Cancer Chemother Pharmacol"},{"key":"e_1_3_1_67_2","unstructured":"Clinicaltrials.gov website. Phase 2 study of bevacizumab in children and young adults with NF2 and progressive vestibular schwannomas (NCT01767792). clinicaltrials.gov\/ct2\/show\/NCT01767792. Updated May 3 2017. Accessed October 10 2017."},{"issue":"2","key":"e_1_3_1_68_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny S","year":"2015","unstructured":"Goutagny S Raymond E Esposito-Farese M. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 2015;122(2):313\u2013320. doi:10.1007\/s11060\u2013014\u20131710\u20130.","journal-title":"J Neurooncol"},{"issue":"3","key":"e_1_3_1_69_2","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas: a systematic review","volume":"101","author":"Ezzat S","year":"2004","unstructured":"Ezzat S Asa SL Couldwell WT. The prevalence of pituitary adenomas: a systematic review. Cancer 2004;101(3):613\u2013619. doi:10.1002\/cncr.20412.","journal-title":"Cancer"},{"issue":"4","key":"e_1_3_1_70_2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011","volume":"16","author":"Ostrom QT","year":"2014","unstructured":"Ostrom QT Gittleman H Liao P. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011. Neuro Oncol 2014;16(suppl 4):iv1\u2013iv63. doi:10.1093\/neuonc\/nou223.","journal-title":"Neuro Oncol"},{"issue":"1","key":"e_1_3_1_71_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11102-010-0253-4","article-title":"Demographic differences in incidence for pituitary adenoma","volume":"14","author":"McDowell BD","year":"2011","unstructured":"McDowell BD Wallace RB Carnahan RM. Demographic differences in incidence for pituitary adenoma. Pituitary 2011;14(1):23\u201330. doi:10.1007\/s11102\u2013010\u20130253\u20134.","journal-title":"Pituitary"},{"issue":"3","key":"e_1_3_1_72_2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.mehy.2008.08.030","article-title":"Rethinking the stalk effect: a new hypothesis explaining suprasellar tumor-induced hyperprolactinemia","volume":"72","author":"Skinner DC","year":"2009","unstructured":"Skinner DC. Rethinking the stalk effect: a new hypothesis explaining suprasellar tumor-induced hyperprolactinemia. Med Hypotheses 2009;72(3):309\u2013310. doi:10.1016\/j.mehy.2008.08.030.","journal-title":"Med Hypotheses"},{"issue":"3","key":"e_1_3_1_73_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11060-014-1386-5","article-title":"The pituitary stalk effect: is it a passing phenomenon?","volume":"117","author":"Bergsneider M","year":"2014","unstructured":"Bergsneider M Mirsadraei L Yong WH. The pituitary stalk effect: is it a passing phenomenon? J Neurooncol 2014;117(3):477\u2013484. doi:10.1007\/s11060\u2013014\u20131386\u20135.","journal-title":"J Neurooncol"},{"issue":"6","key":"e_1_3_1_74_2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13244-014-0362-0","article-title":"Pituitary apoplexy: an update on clinical and imaging features","volume":"5","author":"Boellis A","year":"2014","unstructured":"Boellis A di Napoli A Romano A Bozzao A. Pituitary apoplexy: an update on clinical and imaging features. Insights Imaging 2014;5(6):753\u2013762. doi:10.1007\/s13244\u2013014\u20130362\u20130.","journal-title":"Insights Imaging"},{"issue":"3","key":"e_1_3_1_75_2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1212\/CON.0000000000000467","article-title":"Endocrine emergencies with neurologic manifestations","volume":"23","author":"Ishii M","year":"2017","unstructured":"Ishii M. Endocrine emergencies with neurologic manifestations. Continuum (Minneap Minn) 2017;23(3 Neurology of Systemic Disease):778\u2013801. doi:10.1212\/CON.0000000000000467.","journal-title":"Continuum (Minneap Minn)"},{"issue":"5","key":"e_1_3_1_76_2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch ME","year":"2017","unstructured":"Molitch ME. Diagnosis and treatment of pituitary adenomas: a review. JAMA 2017;317(5):516\u2013524. doi:10.1001\/jama.2016.19699.","journal-title":"JAMA"},{"issue":"7","key":"e_1_3_1_77_2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrendo.2014.64","article-title":"Aggressive pituitary adenomas\u2014diagnosis and emerging treatments","volume":"10","author":"Di Ieva A","year":"2014","unstructured":"Di Ieva A Rotondo F Syro LV. Aggressive pituitary adenomas\u2014diagnosis and emerging treatments. Nat Rev Endocrinol 2014;10(7):423\u2013435. doi:10.1038\/nrendo.2014.64.","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"e_1_3_1_78_2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pharmthera.2008.11.003","article-title":"Pharmacotherapy for adults with tumors of the central nervous system","volume":"121","author":"Schor NF","year":"2009","unstructured":"Schor NF. Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol Ther 2009;121(3):253\u2013264. doi:10.1016\/j.pharmthera.2008.11.003.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"e_1_3_1_79_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1385\/ENDO:28:1:111","article-title":"Treatment of pituitary tumors: pegvisomant","volume":"28","author":"Paisley AN","year":"2005","unstructured":"Paisley AN Drake WM. Treatment of pituitary tumors: pegvisomant. Endocrine 2005;28(1):111\u2013114. doi:10.1385\/ENDO:28:1:111.","journal-title":"Endocrine"},{"issue":"6","key":"e_1_3_1_80_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-013-0052-0","article-title":"Pasireotide: a review of its use in Cushing\u2019s disease","volume":"73","author":"McKeage K","year":"2013","unstructured":"McKeage K. Pasireotide: a review of its use in Cushing\u2019s disease. Drugs 2013;73(6):563\u2013574. doi:10.1007\/s40265\u2013013\u20130052\u20130.","journal-title":"Drugs"},{"issue":"10","key":"e_1_3_1_81_2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao A","year":"2012","unstructured":"Colao A Petersenn S Newell-Price J. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 2012;366(10):914\u2013924. doi:10.1056\/NEJMoa1105743.","journal-title":"N Engl J Med"},{"issue":"1","key":"e_1_3_1_82_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.6061\/clinics\/2012(Sup01)20","article-title":"Temozolomide in aggressive pituitary adenomas and carcinomas","volume":"67","author":"Ortiz LD","year":"2012","unstructured":"Ortiz LD Syro LV Scheithauer BW. Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo) 2012;67(suppl 1):119\u2013123. doi:10.6061\/clinics\/2012(Sup01)20.","journal-title":"Clinics (Sao Paulo)"},{"key":"e_1_3_1_83_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40478-016-0287-6","article-title":"Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles","volume":"4","author":"Ho\u00a8lsken A","year":"2016","unstructured":"Ho\u00a8lsken A Sill M Merkle J. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun 2016;4:20. doi:10.1186\/s40478\u2013016\u20130287\u20136.","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"e_1_3_1_84_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3171\/jns.1998.89.4.0547","article-title":"The descriptive epidemiology of craniopharyngioma","volume":"89","author":"Bunin GR","year":"1998","unstructured":"Bunin GR Surawicz TS Witman PA. The descriptive epidemiology of craniopharyngioma. J Neurosurg 1998;89(4):547\u2013551. doi:10.3171\/jns.1998.89.4.0547.","journal-title":"J Neurosurg"},{"issue":"2","key":"e_1_3_1_85_2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/00006123-200002000-00007","article-title":"Long-term outcomes for surgically resected craniopharyngiomas","volume":"46","author":"Duff J","year":"2000","unstructured":"Duff J Meyer FB Ilstrup DM. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 2000;46(2):291\u2013302; discussion 302\u2013305. doi:10.1097\/00006123\u2013200002000\u201300007.","journal-title":"Neurosurgery"},{"issue":"2","key":"e_1_3_1_86_2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clineuro.2007.10.013","article-title":"Craniopharyngioma: surgical experience of 309 cases in China","volume":"110","author":"Shi XE","year":"2008","unstructured":"Shi XE Wu B Fan T. Craniopharyngioma: surgical experience of 309 cases in China. Clin Neurol Neurosurg 2008;110(2):151\u2013159. doi:10.1016\/j.clineuro.2007.10.013.","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"e_1_3_1_87_2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1210\/jc.2011-2817","article-title":"Markers of recurrence and long-term morbidity in craniopharyngioma: a systematic analysis of 171 patients","volume":"97","author":"Gautier A","year":"2012","unstructured":"Gautier A Godbout A Grosheny C. Markers of recurrence and long-term morbidity in craniopharyngioma: a systematic analysis of 171 patients. J Clin Endocrinol Metab 2012;97(4):1258\u20131267. doi:10.1210\/jc.2011\u20132817.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"e_1_3_1_88_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000120855","article-title":"Pathology of craniopharyngiomas: clinical import of pathological findings","volume":"21","author":"Miller DC","year":"1994","unstructured":"Miller DC. Pathology of craniopharyngiomas: clinical import of pathological findings. Pediatr Neurosurg 1994;21(suppl 1):11\u201317.","journal-title":"Pediatr Neurosurg"},{"issue":"9","key":"e_1_3_1_89_2","first-page":"CD008890","article-title":"Intracystic bleomycin for cystic craniopharyngiomas in children","author":"Zheng J","year":"2014","unstructured":"Zheng J Fang Y Cai BW. Intracystic bleomycin for cystic craniopharyngiomas in children. Cochrane Database Syst Rev 2014;(9):CD008890. doi:10.1002\/14651858.CD008890.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"e_1_3_1_90_2","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.3892\/ol.2016.5119","article-title":"Pituicytoma: a report of three cases and literature review","volume":"12","author":"Yang X","year":"2016","unstructured":"Yang X Liu X Li W Chen D. Pituicytoma: a report of three cases and literature review. Oncol Lett 2016;12(5):3417\u20133422. doi:0.3892\/ol.2016.5119.","journal-title":"Oncol Lett"},{"issue":"9","key":"e_1_3_1_91_2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/epi.12457","article-title":"Dysembryoplastic neuroepithelial tumors: where are we now?","volume":"54","author":"Chassoux F","year":"2013","unstructured":"Chassoux F Daumas-Duport C. Dysembryoplastic neuroepithelial tumors: where are we now? Epilepsia 2013;54(suppl 9):129\u2013134. doi:10.1111\/epi.12457.","journal-title":"Epilepsia"},{"issue":"6","key":"e_1_3_1_92_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.4132\/jptm.2015.10.05","article-title":"Dysembryoplastic neuroepithelial tumors","volume":"49","author":"Suh YL","year":"2015","unstructured":"Suh YL. Dysembryoplastic neuroepithelial tumors. J Pathol Transl Med 2015;49(6):438\u2013449. doi:10.4132\/jptm.2015.10.05.","journal-title":"J Pathol Transl Med"},{"issue":"16","key":"e_1_3_1_93_2","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/WNL.0b013e31826e9aa9","article-title":"Dysembryoplastic neuroepithelial tumors: an MRI-based scheme for epilepsy surgery","volume":"79","author":"Chassoux F","year":"2012","unstructured":"Chassoux F Rodrigo S Mellerio C. Dysembryoplastic neuroepithelial tumors: an MRI-based scheme for epilepsy surgery. Neurology 2012;79(16):1699\u20131707. doi:10.1212\/WNL.0b013e31826e9aa9.","journal-title":"Neurology"},{"issue":"9639","key":"e_1_3_1_94_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo P","year":"2008","unstructured":"Curatolo P Bombardieri R Jozwiak S. Tuberous sclerosis. Lancet 2008;372(9639):657\u2013668. doi:10.1016\/S0140\u20136736(08)61279\u20139.","journal-title":"Lancet"},{"issue":"12","key":"e_1_3_1_95_2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1038\/ejhg.2015.47","article-title":"Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2","volume":"23","author":"Kwiatkowski DJ","year":"2015","unstructured":"Kwiatkowski DJ Palmer MR Jozwiak S. Response to everolimus is seen in TSC-associated SEGAs and angiomyolipomas independent of mutation type and site in TSC1 and TSC2. Eur J Hum Genet 2015;23(12):1665\u20131672. doi:10.1038\/ejhg.2015.47.","journal-title":"Eur J Hum Genet"},{"issue":"13","key":"e_1_3_1_96_2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz DN","year":"2014","unstructured":"Franz DN Belousova E Sparagana S. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 2014;15(13):1513\u20131520. doi:10.1016\/S1470\u20132045(14)70489\u20139.","journal-title":"Lancet Oncol"},{"issue":"23","key":"e_1_3_1_97_2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1212\/WNL.0000000000003400","article-title":"Long-term treatment of epilepsy with everolimus in tuberous sclerosis","volume":"87","author":"Krueger DA","year":"2016","unstructured":"Krueger DA Wilfong AA Mays M. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology 2016;87(23):2408\u20132415. doi:10.1212\/WNL.0000000000003400.","journal-title":"Neurology"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00132979-201712000-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T14:03:09Z","timestamp":1752156189000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":96,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1212\/CON.0000000000000541"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000541","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}